Psyomics Awarded Innovate UK Innovation Loan to Pioneer the Future of NHS Mental Health Technology

London-based healthtech scale-up Psyomics has secured an Innovation Loan from Innovate UK to accelerate the development of its digital mental health platform, beseen™. The funding will enable the company to transition its technology into a regulated medical device designed to streamline NHS mental health pathways and improve clinical decision-making. This investment comes at a critical time for the sector as providers face rising demand and significant workforce shortages, highlighting the growing role of clinical intelligence in modernizing mental healthcare delivery.

Psyomics, a London-based healthtech firm, has obtained debt finance through an Innovate UK Innovation Loan to scale its operations and enhance its digital mental health offerings. The primary focus of this funding is the evolution of the company’s beseen™ platform into a regulated medical device, which aims to provide mental healthcare Trusts with advanced clinical intelligence. According to CEO Dr. Melinda Rees, the collaboration is intended to address the current crisis in mental health waiting lists by building a resilient and intelligent infrastructure for the sector.

The implementation of these new tools is expected to significantly modernize mental health pathways by reducing administrative paperwork and improving the consistency of clinical decisions. Psyomics projects that its innovations will release approximately 85,000 healthcare professional hours back into the system, potentially delivering a 13.2x return on investment for the NHS within the first year. The company already serves a population of over 8 million adults and seeks to establish a new global standard for evidence-based, efficient mental health care.

This strategic investment arrives as the UK healthcare system struggles with a sharp rise in demand for mental health support across all age groups, coupled with sustained workforce shortages. By digitizing legacy systems and expanding community-based support, Psyomics’ technology aligns with national priorities for earlier intervention. The loan not only supports the placement of regulated medical devices on the market but also contributes to the UK economy by creating skilled jobs and strengthening health innovation productivity.